Clinical Trials
67 trialsINDIGO
Boston Scientific Corporation
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
BRAVESST2
Crinetics Pharmaceuticals Inc.
STELLAR-311
Exelixis
STRAP
National Cancer Centre, Singapore
STARTRK-NG
Hoffmann-La Roche
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
Changi General Hospital
Pan-MSI-ACSE
UNICANCER
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
EchoTip AcuCore Post-Market Clinical Study
Cook Group Incorporated
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
METALLICA
MedSIR
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
University of Sao Paulo
SNIPP
University Health Network, Toronto
EVACEL
Federation Francophone de Cancerologie Digestive
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients
Peking Union Medical College Hospital
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Cryoablation of Bone Metastases From Endocrine Tumors
Instituto do Cancer do Estado de São Paulo
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Peking Union Medical College Hospital
MPPGL
Peking Union Medical College Hospital
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
REGOMUNE
Institut Bergonié
Treat ER+ight
Novartis
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
TheraSphere for the Treatment of Liver Metastases
Boston Scientific Corporation
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Fox Chase Cancer Center
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
PIONEER
SpeciCare
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
DEBOXA for Inoperable NET Liver Metastases
Xiangya Hospital of Central South University
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Case Comprehensive Cancer Center
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Wake Forest University Health Sciences
RMPanNET
Fudan University
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
IOUS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
LyREMeNet
Hospices Civils de Lyon
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
AbbVie
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
M.D. Anderson Cancer Center
A Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute